Live Readout Watch · Pre-Result
MEOW-1 Results — Live Tracker
When Okava publishes the MEOW-1 cat GLP-1 trial readout this summer, we'll update this page with the full data within hours. Until then: here's what we're watching for.
6 min read·Updated May 2, 2026·By Iacob Pastina
Pre-readout — Status May 2026No published results yet. The MEOW-1 trial began December 2025 with at least 50 cats. Primary 3-month observation period concluded approximately March 2026. Optional 3-month extension cohort is in run-out. Okava expects results summer 2026 — likely June through August. We're monitoring Okava press releases, dvm360 trade press, and (because Okava's collaborator Vivani Medical is publicly traded) Vivani investor disclosures.
MEOW-1 is the world's first clinical trial of a pet-specific GLP-1 receptor agonist. Whether it succeeds or fails defines the trajectory for the entire pet GLP-1 category. This page will update with the full data the day Okava publishes results.
What Will Be Reported
Expected primary endpoints based on the published trial design:
- •Body weight change at 3 months and 6 months versus baseline and versus control.
- •Body Condition Score (BCS) change on the 9-point veterinary scale — the BCS shift is what veterinarians actually care about.
- •Adverse event profile — nausea, vomiting, decreased appetite, hepatic enzyme elevation (ALT, ALP).
- •Implant tolerability — local reactions at the implant site, infections, dropouts.
- •Owner-reported quality of life measures.
The Three Outcome Scenarios
| Scenario | Body weight Δ at 3mo | AE profile | Field response |
|---|---|---|---|
| Strong success | >8% loss vs control | Mild GI, no hepatic signal | Okava files FDA late 2026. Cat market launch 2027-2028. Industry incumbents (Zoetis, Boehringer, Merck Animal Health, Elanco) accelerate own programs. Investor sentiment for AXTN spikes. |
| Modest success | 4-8% loss vs control | Acceptable, manageable | Okava runs confirmatory trial. FDA path to 2028. Market cap implications mixed — Akston AKS-562c readout becomes the deciding signal for the broader category. |
| Marginal | <4% loss vs control | Acceptable but underwhelming | Commercial viability questionable at $100/mo retail. Okava may pivot or consolidate. Akston Cornell readout becomes critical. Pet GLP-1 category reset to slower trajectory. |
| Failure / safety | No meaningful efficacy OR hepatic signal | Trial concerns | OKV-119 program likely shelved. Field resets to AKS-562c as only remaining feline candidate. Investor confidence in pet GLP-1 category drops. Dog programs delayed. |
Why the Readout Matters Beyond Cats
MEOW-1 is the most-watched veterinary trial of 2026 because it sets three precedents simultaneously:
- FDA-CVM precedent for novel-mechanism vet drugs. The agency's comfort with GLP-1 as an indication will inform how it treats subsequent feline and canine GLP-1 candidates.
- Commercial template for vet biologics. Pricing, distribution (vet-prescribed vs telehealth), and adoption rate will anchor expectations for LOY-002, AKS-562c, and any future canine GLP-1.
- Investor confidence for the category. A successful readout could trigger a wave of capital into veterinary biotech — potentially funding the canine GLP-1 program neither Okava nor Akston has formally announced yet.
Get the readout the day it landsJoin the trial alerts list — one email when Okava publishes MEOW-1 results. We'll publish the full data, the analysis, and the field implications here on this page within hours.
Frequently Asked Questions
When will MEOW-1 results be published?+
Okava expects results summer 2026 — likely June through August. The trial began December 2025 with a 3-month primary observation period and an optional 3-month extension. Treatment phase concluded approximately March 2026, with data analysis ongoing.
Where will Okava publish the results?+
Likely channels: an Okava press release, a peer-reviewed journal submission (potentially JVIM or Veterinary Record), and trade press coverage (dvm360, Veterinary Practice News, Smithsonian which previously covered the trial start). Investor channels for Vivani Medical (Okava's implant manufacturing collaborator, publicly traded) may surface signals via SEC filings.
What's a clinically meaningful weight loss in cats?+
For overweight/obese cats, vets generally consider 4-8% body weight loss over 3 months as meaningful, with 8%+ as a strong signal. Anything below 3% over 3 months is commercially marginal — within the range achievable through diet alone, which is cheaper and safer.
Can I enroll my cat in the MEOW-1 trial?+
Trial enrollment likely closed in late 2025 / early 2026. The trial enrolled at least 50 cats and is now in the data analysis phase. Future trials (potentially expanded cohort or follow-up studies) may open enrollment after the initial readout.
Related
Veterinary disclaimer:This article is for informational purposes only and does not constitute veterinary advice. Always consult a licensed veterinarian before changing your pet's diet, exercise routine, or medication. Information is current as of the publication date but pet pharmaceutical and food formulation details may change.
Looking for human GLP-1 medications instead?
Visit GLP-1 Picks → 42 verified telehealth providers